MAPK3 and neoplasm: In this promising scenario, further investigations will be required to assess the effectiveness of PKCε specific inhibition, used alone or in combination with FGFR, ERK1/2 and autophagy inhibitors, as advanced therapeutic approaches to prevent and/or reverse tumor aggressive phenotypes.